Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nevro Corp. Common Stock (NY: NVRO )

4.050 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nevro Corp. Common Stock

< Previous 1 2 3 4 5 Next >
Where Nevro Stands With Analysts
Via Benzinga
Nevro Secures FDA Nod HFX iQ Spinal Cord Stimulation System For to Personalize Pain Treatment
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
What 4 Analyst Ratings Have To Say About Nevro
Analysts have provided the following ratings for Nevro (NYSE:NVRO) within the last quarter: 
Via Benzinga
Nevro Wins Multiple Coverage Options For Spinal Cord Stimulation In Diabetic Neuropathy
Via Benzinga
Nevro's Return On Capital Employed Overview
  
Via Benzinga
Where Nevro Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Recap: Nevro Q2 Earnings
Nevro (NYSE:NVRO) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 13.41%,... 
Via Benzinga
Expert Ratings for Nevro
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Nevro's Return On Capital Employed Overview
Benzinga Pro data, Nevro (NYSE:NVRO) reported Q1 sales of $87.84 million. Earnings fell to a loss of $34.33 million, resulting in a 13.91% decrease from last quarter. 
Via Benzinga
Where Nevro Stands With Analysts
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: Nevro Q1 Earnings
Nevro (NYSE:NVRO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 10.91%,... 
Via Benzinga
Expert Ratings For Nevro
Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings: 
Via Benzinga
Recap: Nevro Q4 Earnings
Nevro (NYSE:NVRO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro... 
Via Benzinga
Where Nevro Stands With Analysts
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last ... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Nevro: Q3 Earnings Insights
Nevro (NYSE:NVRO) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro reported... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Craig-Hallum cut Zix Corporation (NASDAQ:ZIXI) p... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
Nevro Corp (NVRO) Q3 2021 Earnings Call Transcript
NVRO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.